Full Title
A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered with Enfortumab Vedotin and Pembrolizumab in Participants with Advanced Urothelial CancerPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Samuel Funt’s office at 646-888-4770.
Protocol
26-148
Phase
Phase I (phase 1)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07484022
ClinicalTrials.gov